Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Phase 2/3 Terminated 5 enrolled University of Alabama at Birmingham

NaSingle-groupOpen-labelTreatment

Summary

A non-myeloablative treatment strategy and uniform selection criteria will enable patients with a variety of low grade B-Cell malignancies to attain long term disease control without unacceptably high treatment related mortality.

Timeline

Start: 2008-07
Primary completion: 2013-02
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fludarabine	Small molecule	30 mg/m2	—

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Summary

Timeline

Drugs

Indications